HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies.

Abstract
Treatment of disseminated tuberculosis in children≤6years has not been optimized. The pyrazinamide-containing combination regimen used to treat disseminated tuberculosis in babies and toddlers was extrapolated from adult pulmonary tuberculosis. Due to hepatotoxicity worries, there are no dose-response studies in children. We designed a hollow fiber system model of disseminated intracellular tuberculosis with co-perfused three-dimensional organotypic liver modules to simultaneously test for efficacy and toxicity. We utilized pediatric pharmacokinetics of pyrazinamide and acetaminophen to determine dose-dependent pyrazinamide efficacy and hepatotoxicity. Acetaminophen concentrations that cause hepatotoxicity in children led to elevated liver function tests, while 100mg/kg pyrazinamide did not. Surprisingly, pyrazinamide did not kill intracellular Mycobacterium tuberculosis up to fourfold the standard dose as monotherapy or as combination therapy, despite achieving high intracellular concentrations. Host-pathogen RNA-sequencing revealed lack of a pyrazinamide exposure transcript signature in intracellular bacteria or of phagolysosome acidification on pH imaging. Artificial intelligence algorithms confirmed that pyrazinamide was not predictive of good clinical outcomes in children≤6years who had extrapulmonary tuberculosis. Thus, adding a drug that works inside macrophages could benefit children with disseminated tuberculosis. Our in vitro model can be used to identify such new regimens that could accelerate cure while minimizing toxicity.
AuthorsShashikant Srivastava, Jotam G Pasipanodya, Geetha Ramachandran, Devyani Deshpande, Stephen Shuford, Howland E Crosswell, Kayle N Cirrincione, Carleton M Sherman, Soumya Swaminathan, Tawanda Gumbo
JournalEBioMedicine (EBioMedicine) Vol. 6 Pg. 126-138 (Apr 2016) ISSN: 2352-3964 [Electronic] Netherlands
PMID27211555 (Publication Type: Journal Article)
CopyrightCopyright © 2016 The Authors. Published by Elsevier B.V. All rights reserved.
Chemical References
  • Antitubercular Agents
  • Pyrazinamide
  • Acetaminophen
Topics
  • Acetaminophen (pharmacokinetics, toxicity)
  • Antitubercular Agents (administration & dosage, adverse effects, pharmacokinetics)
  • Cell Line
  • Chemical and Drug Induced Liver Injury (physiopathology)
  • Child, Preschool
  • Coculture Techniques
  • Humans
  • Infant
  • Infant, Newborn
  • Models, Biological
  • Mycobacterium tuberculosis (drug effects)
  • Pyrazinamide (administration & dosage, adverse effects, pharmacokinetics)
  • Toxicity Tests
  • Treatment Outcome
  • Tuberculosis (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: